A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation.
Advanced Solid Tumours|Non-Small Cell Lung Cancer (NSCLC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer (CRC)
DRUG: AZD0022|DRUG: Cetuximab
Incidence of participants with Dose-Limiting Toxicity (DLT), Adverse events (AEs) and Serious Adverse Events (SAEs)., Determine if treatment with AZD0022 as a monotherapy and in combination with other anti-cancer agents is safe and tolerable through the assessment of DLTs, AEs, SAEs, and change from baseline in laboratory parameters, vital signs, and ECGs.

Part A (Dose Escalation) and Part B (Dose Optimisation). DLTs only applicable for Part A., From time of informed consent, through study completion to 30 days post last dose; an average of 2 years|Number of patients who discontinue AZD0022 due to toxicity, To investigate the safety and tolerability of AZD0022 as a monotherapy and in combination with other anti-cancer agents in participants with advanced tumours harbouring a KRASG12D mutation

Part A (Dose Escalation) and Part B (Dose Optimisation), From time of informed consent to 30 days post last dose|ORR (Objective Response Rate), Evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part C (Potential Efficacy Expansion)

Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR), Time from first dose of AZD002 through study completion; approximate duration of 2 years
CR rate (Complete Response), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)

Percentage of participants with a confirmed Complete Response (CR), From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years|DoR (Duration of Response), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).

Time from the date of first documented evidence of CR or PR until date of first documented disease progression or death., From the date of first response until date of disease progression (RECIST 1.1) or death in the absence of disease progression; approximate duration of 2 years.|DCR (Disease Control Rate), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).

Percentage of participants who have a confirmed CR, PR, or Stable Disease (SD) for at least 11 weeks after start of treatment., From first dose (non-randomised study parts) or from randomisation (randomised) until progression. For each patient, this is expected to be at 12 weeks|DRR (Durable Response Rate), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).

Percentage of participants who have a confirmed response (CR/PR) with a duration of at least 3 months., From first documented response up until progression, or the last evaluable assessment in the absence of progression; approximate duration of 2 years.|TTR (Time to Response), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)

Time from first dose/randomisation date until date of first documented evidence of CR or PR per RECIST v1.1, From first dose (non-randomised study parts) or from randomisation (randomised study parts) until the date of documented objective response; approximate duration of 2 years.|PFS (Progression Free Survival), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).

Time from first dose/randomisation date until date of first documented disease progression or death., 'From first dose (non-randomised study parts) or from randomisation (randomised study parts) to progressive disease or death in the absence of disease progression; approximate duration of 2 years|Change in tumour size, To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)

Percentage change in tumor size from baseline per RECIST v1.1, From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|OS (Overall Survival), To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).

Time from first dose/randomisation date until death due to any case., From first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts) to death; approximate duration of 2 years.|Complete Molecular Response (cMR)., To assess the molecular response rate via ctDNA on treatment with AZD0022 as a monotherapy and in combination with other anti-cancer agents

Part A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)., From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|Pharmacokinetics of AZD0022: Maximum plasma concentration of the study drug (Cmax), Maximum observed plasma concentration of the study drug

Part A (Dose Escalation) and Part B (Dose Optimisation), From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|Pharmacokinetics of AZD0022: Time to maximum plasma concentration of the study drug (T-max), Time to maximum observed plasma concentration of the study drug

Part A (Dose Escalation) and Part B (Dose Optimisation), From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|Pharmacokinetics of AZD0022: AuClast (Area Under the Plasma Contentration-Time Curve to the Last Measurable Plasma Concentration), A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.

Part A (Dose Escalation) and Part B (Dose Optimisation), From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022 until Cycle 3 Day 1.|Pharmacokinetics of AZD0022: Terminal elimination half-life (t 1/2), Terminal elimination half life.

Part A (Dose Escalation) and Part B (Dose Optimisation), From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022 until Cycle 3 Day 1.|Incidence of participants with Adverse events (AEs) and Serious Adverse Events (SAEs)., Determine if treatment with AZD0022 as a monotherapy and in combination with other anticancer agents is safe and tolerable through the assessment of AEs, SAEs, and change from baseline in laboratory parameters, vital signs, and ECGs.

Part C (Potential Efficacy Expansion)., From time of informed consent, through study completion to 30 days post last dose; an average of 2 years|Number of patients who discontinue AZD0022 due to toxicity, To further assess the safety and tolerability of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Part C (Potential Efficacy Expansion)., From time of informed consent, through study completion to 30 days post last dose; an average of 2 years|TDT (Time to Discontinuation of Treatment), To estimate the anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents.

Part C (Potential Efficacy Expansion)

Time from first dose/randomisation date until discontinuation of treatment or death due to any case., From first dose until discontinuation of treatment for any reason; approximate duration of 2 years.|TFST (Time to First Subsequent Anti-Cancer), To estimate the anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents.

Part C (Potential Efficacy Expansion).

Time from first dose/randomisation date until start of first subsequent anti-cancer therapy after discontinuation of study treatment, or death due to any cause., From date of first dose until start date of the first subsequent anti-cancer therapy after discontinuation of study treatment, or death; approximate duration of 2 years.|Change in phospho-ERK, To assess KRAS pathway inhibition on treatment with AZD0022 as monotherapy

Module 1 Part A (Dose Escalation), Module 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)\*

Module 2 Part A (Dose Escalation), Module 2 Part B (Dose Optimisation) and Module 2 Part C (Potential efficacy expansion)\*

\*Potential Efficacy Expansion at Sponsor discretion based on emerging data., From baseline, at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|Geometric mean and 90% CI for the ratio of fed:fasted in AUClast and Cmax for food-effect cohort., To characterise the effect of food on AZD0022 as monotherapy

Module 1 Food-effect only, From first dose, at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.|PFS (Progression Free Survival) by BICR, To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Module 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)

Module 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion), From first dose (non-randomised study parts) or from randomisation (randomised study parts) to progressive disease or death in the absence of disease progression; approximate duration of 2 years|ORR (Objective Response Rate) by BICR, To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Module 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)

Module 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion), From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years|DoR (Duration of Rate) by BICR, To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Module 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)

Module 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion), From the date of first response until date of disease progression (RECIST 1.1) or death in the absence of disease progression; approximate duration of 2 years.|ORR (Objective Response Rate) by Investigator, To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents

Radiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)

Module 1 Part A (Dose Escalation) and Module 1 Part B (Dose Optimisation)

Module 2 Part A (Dose Escalation) and Module 2 Part B (Dose Optimisation), From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years
This first time in human, open-label, multi-centre study will administer AZD0022 orally to participants with tumours harbouring a KRASG12D mutation.

This study will have initially 2 modules.

* Module 1: AZD0022 monotherapy
* Module 2: AZD0022 in combination with other anti-cancer agents (Cetuximab)

Each Module has 3 parts. Dose Escalation (Part A), Dose Optimisation (Part B) and Potential Efficacy Expansion (Part C).